Safety, Clinical Activity and Biomarker Results from a Phase lb Study of Erlotinib plus Atezolizumab in Advanced CrossMark NSCLC

被引：13

作者：

Rudin, Charles ^{[1
]}

Cervantes, Andres ^{[2
]}

Dowlati, Afshin ^{[3
]}

Besse, Benjamin ^{[4
]}

Ma, Brigette ^{[5
]}

Costa, Daniel ^{[6
]}

Schmid, Peter ^{[7
]}

Heist, Rebecca ^{[8
]}

Villaflor, Victoria ^{[9
]}

Sarkar, Indrani ^{[10
]}

Huseni, Mahrukh ^{[10
]}

Foster, Paul ^{[10
]}

O'Hear, Carol ^{[10
]}

Gettingeril, Scott ^{[11
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Valencia, Valencia, Spain

[3] Univ Hosp Case Med Ctr, Cleveland, OH USA

[4] Gustave Roussy, Dept Canc Med, Orsay, France

[5] Chinese Univ Hong Kong, Phase Clin Trial Ctr 1, Hong Kong, Hong Kong, Peoples R China

[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[7] Barts Canc Inst, London, England

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Northwestern Univ, Chicago, IL 60611 USA

[10] Genentech Inc, San Francisco, CA 94080 USA

[11] Yale Canc Ctr, New Haven, CT USA

来源：

关键词：

atezolizumab; NSCLC; Immunotherapy; Erlotinib;

D O I：

10.1016/j.jtho.2016.11.1841

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02c-046

引用

页码：S1302 / S1303

页数：2